- Home
- SCNI vs NVVE Comparison
SCNI vs NVVE Comparison
Compare SCNI & NVVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- NVVE
- Stock Information
- Founded
- SCNI 2003
- NVVE 1996
- Country
- SCNI Israel
- NVVE United States
- Employees
- SCNI N/A
- NVVE N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- NVVE Oil Refining/Marketing
- Sector
- SCNI Health Care
- NVVE Energy
- Exchange
- SCNI Nasdaq
- NVVE Nasdaq
- Market Cap
- SCNI 4.6M
- NVVE 4.2M
- IPO Year
- SCNI N/A
- NVVE N/A
- Fundamental
- Price
- SCNI $1.45
- NVVE $0.21
- Analyst Decision
- SCNI
- NVVE
- Analyst Count
- SCNI 0
- NVVE 0
- Target Price
- SCNI N/A
- NVVE N/A
- AVG Volume (30 Days)
- SCNI 95.7K
- NVVE 1.9M
- Earning Date
- SCNI 11-21-2025
- NVVE 11-11-2025
- Dividend Yield
- SCNI N/A
- NVVE N/A
- EPS Growth
- SCNI N/A
- NVVE N/A
- EPS
- SCNI 0.26
- NVVE N/A
- Revenue
- SCNI $1,147,000.00
- NVVE $4,949,747.00
- Revenue This Year
- SCNI N/A
- NVVE $892.33
- Revenue Next Year
- SCNI N/A
- NVVE N/A
- P/E Ratio
- SCNI $5.50
- NVVE N/A
- Revenue Growth
- SCNI 303.87
- NVVE N/A
- 52 Week Low
- SCNI $1.20
- NVVE $0.18
- 52 Week High
- SCNI $6.18
- NVVE $5.02
- Technical
- Relative Strength Index (RSI)
- SCNI 50.03
- NVVE 37.45
- Support Level
- SCNI $1.43
- NVVE $0.21
- Resistance Level
- SCNI $1.52
- NVVE $0.25
- Average True Range (ATR)
- SCNI 0.09
- NVVE 0.02
- MACD
- SCNI 0.01
- NVVE 0.01
- Stochastic Oscillator
- SCNI 53.06
- NVVE 23.53
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.